// App-Quantinova.ai

: INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis: A Phase 1 Study

Researchers

Presenter

  • Justin Watts

Principal Investigators

  • Anthony M. Hunter

  • Alessandra Iurlo

  • Blanca Xicoy

  • Francesca Palandri

  • Brandi Reeves

  • Alessandro M. Vannucchi

  • Xuejun Chen

  • Francis Seguy

  • Feng Zhou

  • Fred Zheng

  • Pankit Vachhani

Medical Centers

  • Incyte Biosciences International Sàrl, Morges, Switzerland

  • Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy

  • AOU Careggi, University of Florence, Florence, Italy

  • Sylvester Cancer Center, University of Miami, Miami, FL

  • O'Neal Comprehensive Cancer Center at UAB, Birmingham, AL

  • Emory University School of Medicine, Atlanta, GA

  • University of North Carolina School of Medicine, Chapel Hill, NC

  • HU German Trias i Pujol - Institut Català d’ Oncologia, Barcelona, Spain

Locations

  • Switzerland

  • United States

  • Italy

  • Spain

Companies

  • Incyte Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Myelofibrosis

  • Anemia

Biomarkers

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • Safety

  • Pharmacokinetics

  • Tolerability

  • Dose Escalation

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved